Keytruda is an immunotherapy drug that is used to treat different types of cancers. The drug helps the body's own immune system to fight the cancer cells. Developed and sold by Merck & Co., the drug ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...
Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...
This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...
Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in ...
The message Tolaney wants patients with newly diagnosed metastatic TNBC to take away from these findings is one of clarity ...
Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...
27d
Melanoma is the deadliest form of skin cancer. A new vaccine-drug combo could slash recurring cases
Most recurrences of the deadliest form of skin cancer develop within the first 2-3 years after treatment, but melanoma can recur even over a decade later, according to the AIM at Melanoma Foundation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results